In-vitro Inflammatory Bowel Disease Diagnostic Market (Product: Assays/Biomarker and Analyzers; and End User: Diagnostic Laboratories, Hospitals, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Growing Prevalence of Inflammatory Bowel Diseases to Aid Market Growth

Inflammatory bowel disease is highly prevalent around several regions of the world and often affects the quality of life among patients. The growing prevalence of inflammatory bowel disease has compelled healthcare experts around the world to aggressively work toward the discovery of effective and in-vitro inflammatory bowel disease diagnostics due to which, the global in-vitro inflammatory bowel disease diagnostics market has witnessed considerable movement over the past few years. In-vitro inflammatory bowel disease diagnostics primarily relies on endoscopy– an invasive procedure wherein anesthesia and bowel preparation is required. Although endoscopy has largely remained a go-to medical procedure, the negative effect on the patient’s quality of life continues to remain a major challenge.

In the wake of these existing challenges, a range of new technologies and advancements, including in-vitro inflammatory bowel disease diagnostics is currently gaining considerable adoption. The recent advancements in positron emission tomography (PET), especially with the use of antibody-conjugated tracers, have offered promising results, while treating inflammatory bowel disease, a factor that is expected to propel the growth of the global in-vitro inflammatory bowel disease diagnostics market during the assessment period.

Research & Development Activities to Remain Pivotal for Global Market

Due to the growing prevalence of inflammatory bowel diseases, novel biologics are steadily being developed across laboratories and hitting clinics around the world. As players involved in the current in-vitro inflammatory bowel disease diagnostics market landscape are increasingly focusing on gaining approval of the FDA, the race toward discovering the most efficient and cost-effective in-vitro inflammatory bowel disease diagnostics continues to shift gears. In addition, as healthcare providers are increasingly emphasizing on improving the overall well-being of the patient, with it, efforts to improve in-vitro inflammatory bowel disease diagnostics continue to grow at a rapid pace. Research and development activities are projected to play a key role in the overall growth of the global in-vitro inflammatory bowel disease diagnostics market during the assessment period. At the moment, researchers around the world are increasingly leveraging high throughput in-vitro assays to discover the most effective compounds. The safety, longevity, and overall effectiveness of these compounds are being tested to minimize the prevalence of inflammatory bowel diseases.

Get a glimpse of the in-depth analysis through our Report Brochure

While researchers continue to take steps to improve the efficacy of in-vitro inflammatory bowel disease diagnostics, scientists are also focusing on minimizing research expenses.

Growing Adoption of Biomarkers and Analyzers to Fuel Market Growth

The growing prevalence of Crohn’s disease (CD) and ulcerative colitis (UC) in several regions of the world has played a key role in boosting the adoption of biomarkers and analyzers, which, in turn, is expected to propel the growth of the global in-vitro inflammatory bowel disease diagnostics market during the assessment period. The demand for predictive biomarkers has witnessed consistent growth as the need to efficiently assess the mucosal disease activity in inflammatory bowel diseases has become imperative. Serum-based biomarkers have gained considerable traction across the global in-vitro inflammatory bowel disease diagnostics market in recent times and as per current observations, this trend is likely to provide a considerable push to the growth of the market for in-vitro inflammatory bowel disease diagnostics.

Demand to Remain Sluggish amid COVID-19 Pandemic

The healthcare sector has arguable remained one of the busiest core sectors during the ongoing COVID-19 pandemic, as researchers, scientists, and other stakeholders in the healthcare sector are increasingly focusing on discovering vaccines to contain the novel coronavirus. The progress in in-vitro inflammatory bowel disease diagnostics has remained relative slower. Although research and development activities are expected to continue during the ongoing pandemic, the adoption of in-vitro inflammatory bowel disease diagnostics is expected to remain sluggish, particularly in 2020 due to the fear among patients pertaining to contracting the novel coronavirus in hospitals.

Analysts’ Viewpoint

The global in-vitro inflammatory bowel disease diagnostics market is expected to expand at a CAGR of ~4% during the forecast period. The market growth can be attributed to factors, including growing prevalence of inflammatory bowel diseases around the world, research and development activities, technological advancements, growing interest and adoption of minimally invasive procedures, and increasing emphasis on improving patient well-being. While the market growth will remain slower than initial projections in 2020 due to the ongoing COVID-19 pandemic, the market is expected to show signs of recovery during the last quarter of 2020.

In-vitro Inflammatory Bowel Disease Diagnostic Market: Overview

Inflammatory bowel disease (IBD) is a chronic disease, which is used to describe disorders that involve chronic inflammation of the digestive tract. Types of IBD include ulcerative colitis and Crohn's disease.

Fecal and serologic biomarkers can be used in the diagnosis and management of inflammatory bowel disease (IBD). Fecal markers, such as calprotectin and lactoferrin have been studied for their ability to identify patients with IBD, assess disease activity, and predict relapse.

High prevalence of IBD boosts the in-vitro inflammatory bowel disease diagnostic market. In Europe, it is estimated that around 2.5 to 3 million people are affected by inflammatory bowel disease per year.

In-vitro Inflammatory Bowel Disease Diagnostic: Market Drivers

According to CDC data, in 2015, an estimated 1.3% of adults in the U.S., which is around 3 million reported being diagnosed with IBD, either Crohn's disease or ulcerative colitis. Highest incidence and prevalence of IBD is observed in Scandinavia and the U.K. Incidence of Crohn’s disease in Europe ranges from 0.5 to 10.6 cases per 100,000 people per year, while incidence of ulcerative colitis ranges from 0.9 to 24.3 per 100,000 persons per year.

According to IBD Support Australia Incorporated, around 61,000 people in Australia are affected by inflammatory bowel disease of which, around 28,000 people are affected by Crohn’s disease and 33,000 are affected by ulcerative colitis

Rise in Demand for Less-invasive, Resource-benefit, and Cost-effective Diagnostic Modalities

Diagnostic and prognostic features of IBD are usually based on a combination of clinical, laboratory tests, radiology, endoscopy, and pathology aspects. Laboratory biomarkers are noninvasive or micro-invasive indices that are more rapid and cost less as compared to other techniques, thus relieving physiological and financial burden for patients. The use of biomarkers for diagnosis and management of IBD is still necessary. Descriptions of immunological pathway abnormalities in IBD improve assessment to identify the patient’s disease status, and relative risk of progression to complicated disease behaviors, and this information may ultimately influence therapeutic decisions.

Hence, high availability, easy access, high awareness, and cost-effectiveness provide in-vitro inflammatory bowel disease diagnostic a cutting edge over other options

Market Segmentation: In-vitro Inflammatory Bowel Disease Diagnostic Market

In terms of product, the global in-vitro inflammatory bowel disease diagnostic market has been divided into assays/biomarker and analyzers. The assays/biomarker segment has been further subdivided into calprotectin, lactoferrin, bile acids, h. pylori sa, pancreatic elastase, and others.

Based on end user, the global in-vitro inflammatory bowel disease diagnostic market has been classified into diagnostic laboratories, hospitals, and research institutes

Each of the segments has been analyzed in detail for in-vitro inflammatory bowel disease diagnostic market trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The in-vitro inflammatory bowel disease diagnostic market report provides current and future value (US$ Mn) for each of these segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030, along with market size estimations.

Regional Overview: In-vitro Inflammatory Bowel Disease Diagnostic Market

In terms of region, the global in-vitro inflammatory bowel disease diagnostic market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

High prevalence of diseases and well-established healthcare infrastructure that enables proper diagnosis of inflammatory bowel disease are responsible for high market share of the region. According to a paper published in Gastroenterology & Hepatology journal, in 2017, there were 6.8 million cases of inflammatory bowel disease globally, and the highest prevalence rate in 2017 occurred in high-income North America.

The current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030

The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market share and in the decision-making process

Major Players

The report concludes with the company profiles section that includes key information about the major players in the in-vitro inflammatory bowel disease diagnostic market

Leading players analyzed in the report are 

• DiaSorin S.p.A
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Abbott
• Quidel Corporation
• American Laboratory Products Company (ALPCO)
• Certest Biotec SL.
• Biosystems S.A.

Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Key Questions Answered in In-vitro Inflammatory Bowel Disease Diagnostic Market Report

• What is the sales/revenue generated by in-vitro inflammatory bowel disease diagnostic products across all regions during the forecast period?
• What are the opportunities in the global in-vitro inflammatory bowel disease diagnostic market?
• What are the major drivers, restraints, opportunities, and threats in the global market?
• Which region is set to expand at the fastest CAGR during the forecast period?
• Which product segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

In-vitro Inflammatory Bowel Disease Diagnostic Market – Segmentation

Product

• Assays/Biomarker
• Analyzers

End User

• Diagnostic Laboratories
• Hospitals
• Research Institute

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global In-vitro Inflammatory Bowel Disease Diagnostic Market 

4. Market Overview

    4.1.  Introduction & Overview

    4.2. Product Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities 

    4.4. Global In-vitro Inflammatory Bowel Disease Diagnostic Market Analysis and Forecast, 2018–2030

5. Market Outlook 

    5.1. Disease Prevalence & Incidence Rate globally with key countries

    5.2. Key Industry Developments

    5.3. Fecal Biomarkers – Advancement 

6. Global In-vitro Inflammatory Bowel Disease Diagnostic Market Analysis and Forecast, by Product

    6.1. Introduction & Definition

    6.2. Global In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Product, 2018–2030

        6.2.1. Assays/Biomarker

            6.2.1.1. Calprotectin

            6.2.1.2. Lactoferrin

            6.2.1.3. Bile Acids

            6.2.1.4. H. pylori SA

            6.2.1.5. Pancreatic Elastase

            6.2.1.6. Others

        6.2.2. Analyzers

    6.3. Global In-vitro Inflammatory Bowel Disease Diagnostic Market Attractiveness Analysis, by Product

7. Global In-vitro Inflammatory Bowel Disease Diagnostic Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Global In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$) Forecast, by End-user, 2018–2030

        7.2.1. Diagnostic Laboratories

        7.2.2. Hospitals

        7.2.3. Research Institutes

    7.3. Global In-vitro Inflammatory Bowel Disease Diagnostic Market Attractiveness Analysis, by End-user

8. Global In-vitro Inflammatory Bowel Disease Diagnostic Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Global In-vitro Inflammatory Bowel Disease Diagnostic Market Attractiveness Analysis, by Region

9. North America In-vitro Inflammatory Bowel Disease Diagnostic Market Analysis and Forecast

    9.1. Introduction

    9.2. North America In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Product, 2018–2030

        9.2.1. Assays/Biomarker

            9.2.1.1. Calprotectin

            9.2.1.2. Lactoferrin

            9.2.1.3. Bile Acids

            9.2.1.4. H. pylori SA

            9.2.1.5. Pancreatic Elastase

            9.2.1.6. Others

        9.2.2. Analyzers

    9.3. North America In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by End-user, 2018–2030

        9.3.1. Diagnostic Laboratories

        9.3.2. Hospitals

        9.3.3. Research Institutes

    9.4. North America In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Country, 2018–2030

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America In-vitro Inflammatory Bowel Disease Diagnostic Market Attractiveness Analysis

        9.5.1. By Product

        9.5.2. By End-user

        9.5.3. By Country 

10. Europe In-vitro Inflammatory Bowel Disease Diagnostic Market Analysis and Forecast

    10.1. Introduction

    10.2. Europe In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Product, 2018–2030

        10.2.1. Assays/Biomarker

            10.2.1.1. Calprotectin

            10.2.1.2. Lactoferrin

            10.2.1.3. Bile Acids

            10.2.1.4. H. pylori SA

            10.2.1.5. Pancreatic Elastase

            10.2.1.6. Others

        10.2.2. Analyzers

    10.3. Europe In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by End-user, 2018–2030

        10.3.1. Diagnostic Laboratories

        10.3.2. Hospitals

        10.3.3. Research Institutes

    10.4. Europe In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe In-vitro Inflammatory Bowel Disease Diagnostic Market Attractiveness Analysis

        10.5.1. By Product

        10.5.2. By End-user

        10.5.3. By Country/Sub-region

11. Asia Pacific In-vitro Inflammatory Bowel Disease Diagnostic Market Analysis and Forecast

    11.1. Introduction

    11.2. Asia Pacific In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Product, 2018–2030

        11.2.1. Assays/Biomarker

            11.2.1.1. Calprotectin

            11.2.1.2. Lactoferrin

            11.2.1.3. Bile Acids

            11.2.1.4. H. pylori SA

            11.2.1.5. Pancreatic Elastase

            11.2.1.6. Others

        11.2.2. Analyzers

    11.3. Asia Pacific In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by End-user, 2018–2030

        11.3.1. Diagnostic Laboratories

        11.3.2. Hospitals

        11.3.3. Research Institutes

    11.4. Asia Pacific In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific In-vitro Inflammatory Bowel Disease Diagnostic Market Attractiveness Analysis

        11.5.1. By Product

        11.5.2. By End-user

        11.5.3. By Country/Sub-region

12. Latin America In-vitro Inflammatory Bowel Disease Diagnostic Market Analysis and Forecast

    12.1. Introduction

    12.2. Latin America In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Product, 2018–2030

        12.2.1. Assays/Biomarker

            12.2.1.1. Calprotectin

            12.2.1.2. Lactoferrin

            12.2.1.3. Bile Acids

            12.2.1.4. H. pylori SA

            12.2.1.5. Pancreatic Elastase

            12.2.1.6. Others

        12.2.2. Analyzers

    12.3. Latin America In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by End-user, 2018–2030

        12.3.1. Diagnostic Laboratories

        12.3.2. Hospitals

        12.3.3. Research Institutes

    12.4. Latin America In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America In-vitro Inflammatory Bowel Disease Diagnostic Market Attractiveness Analysis

        12.5.1. By Product

        12.5.2. By End-user

        12.5.3. By Country/Sub-region

13. Middle East & Africa In-vitro Inflammatory Bowel Disease Diagnostic Market Analysis and Forecast

    13.1. Introduction

    13.2. Middle East & Africa In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Product, 2018–2030

        13.2.1. Assays/Biomarker

            13.2.1.1. Calprotectin

            13.2.1.2. Lactoferrin

            13.2.1.3. Bile Acids

            13.2.1.4. H. pylori SA

            13.2.1.5. Pancreatic Elastase

            13.2.1.6. Others

        13.2.2. Analyzers

    13.3. Middle East & Africa In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by End-user, 2018–2030

        13.3.1. Diagnostic Laboratories

        13.3.2. Hospitals

        13.3.3. Research Institutes

    13.4. Middle East & Africa In-vitro Inflammatory Bowel Disease Diagnostic Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa In-vitro Inflammatory Bowel Disease Diagnostic Market Attractiveness Analysis

        13.5.1. By Product

        13.5.2. By End-user

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Position Analysis, by Company, 2019

    14.2. Company Profiles

        14.2.1. DiaSorin S.p.A

            14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.1.2. Company Financials

            14.2.1.3. Growth Strategies

            14.2.1.4. SWOT Analysis

        14.2.2. F. Hoffmann-La Roche Ltd 

            14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.2.2. Company Financials

            14.2.2.3. Growth Strategies

            14.2.2.4. SWOT Analysis

        14.2.3. Siemens Healthineers AG 

            14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.3.2. Company Financials

            14.2.3.3. Growth Strategies

            14.2.3.4. SWOT Analysis

        14.2.4. Abbott 

            14.2.4.1. Company Overview (HQ, Business Segments)

            14.2.4.2. Company Financials

            14.2.4.3. Growth Strategies

            14.2.4.4. SWOT Analysis

        14.2.5. Quidel Corporation

            14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.5.2. Company Financials

            14.2.5.3. Growth Strategies

            14.2.5.4. SWOT Analysis

        14.2.6. BÜHLMANN Laboratories AG

            14.2.6.1. Company Overview (HQ, Business Segments)

            14.2.6.2. Growth Strategies

            14.2.6.3. SWOT Analysis

        14.2.7. American Laboratory Products Company (ALPCO) 

            14.2.7.1. Company Overview (HQ, Business Segments)

            14.2.7.2. Growth Strategies

            14.2.7.3. SWOT Analysis

        14.2.8. Certest Biotec SL

            14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.8.2. Growth Strategies

            14.2.8.3. SWOT Analysis

        14.2.9. Biosystems S.A. 

            14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.9.2. Growth Strategies

            14.2.9.3. SWOT Analysis